CTXR Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 22:00):

Stats
Dagens volum	2.77M
Gjennomsnittsvolum	881 503
Markedsverdi	105.77M
EPS	$-0.0700 ( 2024-02-09 )
Neste inntjeningsdato	( $-0.0600 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.56
ATR14	$0.00200 (0.30%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-03	Mazur Leonard L	Buy	1 165 048	Warrant to Purchase Common Stock
2024-04-03	Mazur Leonard L	Sell	1 165 048	Warrant to Purchase Common Stock
2024-04-03	Holubiak Myron Z	Buy	129 450	Warrant to Purchase Common Stock
2024-04-03	Holubiak Myron Z	Sell	129 450	Warrant to Purchase Common Stock
2024-03-14	Smith Robert Joseph	Buy	75 000	Stock Option (Right to Purchase Common Stock)

INSIDER POWER
43.34
Last 96 transactions
Buy: 27 334 255 \| Sell: 1 367 765

Volum Korrelasjon

Lang: 0.26 (neutral)

Kort: -0.17 (neutral)

Signal:(48.664) Neutral

Citius Pharmaceuticals Korrelasjon

10 Mest positive korrelasjoner
FICS	0.886
HEAR	0.877
RNEM	0.868
VIGI	0.866
NTRSO	0.865
RMRM	0.861
PID	0.86
TCON	0.856
TZOO	0.856
GAINL	0.854

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Citius Pharmaceuticals Korrelasjon - Valuta/Råvare

0.00
( neutral )

0.01
( neutral )

Citius Pharmaceuticals Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-194 316 (0.00 %)
EPS:	$-0.220

FY	2023
Omsetning:	$0
Bruttogevinst:	$-194 316 (0.00 %)
EPS:	$-0.220

FY	2022
Omsetning:	$0
Bruttogevinst:	$-179 677 (0.00 %)
EPS:	$-0.230

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.230

Financial Reports:

No articles found.

Citius Pharmaceuticals

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.